The number of older adults with cancer is rising, and the United States population is aging. In 2011, the “baby boom” generation began turning 65, and the U.S. population aged 65 and older is expected to double by 2030. Because cancer is a disease associated with aging, this trend is anticipated to increase the incidence of cancer among older adults by 67%.1 Despite this, enrollment in cancer clinical trials favors a younger population,2-4 and few trials specifically focus on the unique issues that affect older patients. Consequently, little evidence-based data are available on the care of the growing number of older adults with cancer. To bridge this gap, a U13 conference grant, “Geriatric Oncology Research to Improve Clinical Care,” brought together multidisciplinary investigators from geriatrics and oncology to identify the areas of highest research priorities in cancer and aging. The first U13 Conference, “Biological, Clinical, and Psychosocial Correlates at the Interface of Aging and Cancer Research,” established a collaboration among the Cancer and Aging Research Group (CARG), the National Institute of Aging, and the National Cancer Institute. The first conference was designed to identify research goals and factors that would help shape geriatric oncology research. As part of this conference, participants with expertise in cancer and aging were asked to list the 5 most important areas of research in oncology/hematology and geriatrics. Here, we review their responses and the rationale for these research directions.
Smith BD, Smith GL, Hurria A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–2765.
Lewis JH, Kilgore ML, Goldman DP. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383–1389.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720–2726.
Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626–4631.
Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005;11:461–473.
Hurria A, Togawa K, Mohile SG. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457–3465.
Hurria A, Cohen HJ, Extermann M. Geriatric oncology research in the cooperative groups: a report of a SIOG Special Meeting. J Geriatr Oncol 2010;1:40–44.
Extermann M, Boler I, Reich RR. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2011; in press.
Hurria A, Cirrincione CT, Muss HB. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011;29:1290–1296.
Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550–556.